Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Acquisitions & Divestments: 2020-2024

Historic Change in Acquisitions & Divestments for Kymera Therapeutics (KYMR) over the last 5 years, with Dec 2024 value amounting to $510.0 million.

  • Kymera Therapeutics' Change in Acquisitions & Divestments fell 4.08% to $132.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $532.1 million, marking a year-over-year increase of 21.44%. This contributed to the annual value of $510.0 million for FY2024, which is 40.29% up from last year.
  • Per Kymera Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $510.0 million for FY2024, which was up 40.29% from $363.5 million recorded in FY2023.
  • Kymera Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $510.0 million during FY2024, with a 5-year trough of $115.9 million in FY2020.
  • Over the past 3 years, Kymera Therapeutics' median Change in Acquisitions & Divestments value was $469.3 million (recorded in 2022), while the average stood at $447.6 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 209.06% in 2021, then dropped by 22.55% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $115.9 million in 2020, then surged by 209.06% to $358.2 million in 2021, then soared by 31.04% to $469.3 million in 2022, then decreased by 22.55% to $363.5 million in 2023, then surged by 40.29% to $510.0 million in 2024.